---
title: 'ABBV-319: A CD19-targeting glucocorticoid receptor modulator antibody-drug
  conjugate therapy for B-cell malignancies'
date: '2024-05-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38701407/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240504180813&v=2.18.0.post9+e462414
source: Blood
description: Glucocorticoids are key components of the current standard-of-care regimens
  (e.g., R-CHOP, EPOCH-R, Hyper-CVAD) for treatment of B-cell malignancy. However,
  systemic glucocorticoid treatment is associated with several adverse events. CD19
  displays restricted expression in normal B-cells and is up-regulated in B-cell malignancies.
  ABBV-319 is a CD19-targeting antibody-drug conjugate (ADC) engineered to reduce
  glucocorticoid-associated toxicities while possessing three distinct mechanisms
  ...
disable_comments: true
---
Glucocorticoids are key components of the current standard-of-care regimens (e.g., R-CHOP, EPOCH-R, Hyper-CVAD) for treatment of B-cell malignancy. However, systemic glucocorticoid treatment is associated with several adverse events. CD19 displays restricted expression in normal B-cells and is up-regulated in B-cell malignancies. ABBV-319 is a CD19-targeting antibody-drug conjugate (ADC) engineered to reduce glucocorticoid-associated toxicities while possessing three distinct mechanisms ...